Nabriva Therapeutics PLC (NBRVF)

[runcaly]

NABRIVA TO PRESENT DATA FROM XENLETA (LEFAMULIN) AND CONTEPO (FOSFOMYCIN) DEVELOPMENT PROGRAMS AT IDWEEK 2019

DUBLIN, Ireland, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that data from its XENLETA™ (lefamulin) and CONTEPO™ (fosfomycin) clinical development programs will be presented at IDWeek 2019, to be held October 2-9 in Washington, D.C.

Nabriva, along with its collaborators, will present a total of 14 posters, including 11 for lefamulin and three for fosfomycin. Lefamulin data being presented has been generated from the company’s community-acquired bacterial pneumonia (CABP) clinical trial and in vitro surveillance programs. In addition, the company will present clinical data for CONTEPO from the Phase 2/3 pivotal study for the treatment of complicated urinary tract infections (cUTIs) as well as epidemiologic and prevalence data of U.S. hospitalized patients with difficult-to-treat, drug-....